Finance

Lists
603235:SHA
Jiangxi Tianxin Pharmaceutical Co Ltd
CNÂ¥25.16
-1.80%
(-0.46) 1D
Sep 11, 3:00:05 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 603235...
Open
CNÂ¥25.62
High
CNÂ¥25.62
Low
CNÂ¥25.10
Mkt. cap
11.01B
Avg. vol.
709.16K
Volume
785.92K
Dividend
2.19%
Quarterly dividend
CNÂ¥0.14
Ex-dividend date
Jul 1, 2026
P/E ratio
19.94
52-wk high
CNÂ¥28.75
52-wk low
CNÂ¥21.58
EPS
CNÂ¥1.26
No. of employees
3K
Open
CNÂ¥25.62
High
CNÂ¥25.62
Low
CNÂ¥25.10
Mkt. cap
11.01B
Avg. vol.
709.16K
Volume
785.92K
Dividend
2.19%
Quarterly dividend
CNÂ¥0.14
Ex-dividend date
Jul 1, 2026
P/E ratio
19.94
52-wk high
CNÂ¥28.75
52-wk low
CNÂ¥21.58
EPS
CNÂ¥1.26
No. of employees
3K
About Jiangxi Tianxin Pharmaceutical Co Ltd
CEO-
Employees2.89K
FoundedSep 24, 2004
Headquarters-
SectorPersonal care products
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
508.60M
714.10M
639.76M
669.62M
Cost of goods sold
292.05M
477.79M
383.91M
387.72M
Cost of revenue
292.05M
477.79M
383.91M
387.72M
Research and development expenses
28.86M
29.20M
20.63M
26.57M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
53.07M
67.69M
49.46M
49.45M
Operating expense
59.24M
136.56M
70.18M
75.02M
Total operating expenses
351.28M
614.35M
454.08M
462.74M
Operating income
157.31M
99.74M
185.67M
206.89M
Other non operating income
6.85M
-7.39M
-7.99M
-18.29M
EBT including unusual items
127.06M
152.78M
176.75M
203.69M
EBT excluding unusual items
161.65M
99.71M
176.82M
194.19M
Income tax expense
22.77M
21.50M
29.74M
31.37M
Effective tax rate
17.92%
14.07%
16.83%
15.40%
Other operating expenses
-21.03M
36.49M
-664.38K
-846.37K
Net income
104.29M
131.28M
147.00M
172.32M
Net profit margin
20.51%
18.38%
22.98%
25.73%
Earnings per share
-
-
-
-
Interest and investment income
11.84M
17.87M
9.07M
9.94M
Interest expense
-5.32M
-
-9.94M
-4.35M
Net interest expenses
6.52M
17.87M
-867.88K
5.59M
Depreciation and amortization charges
-
-
-
-
EBITDA
195.07M
146.26M
232.19M
264.37M
Gain or loss from assets sale
-
505.17K
-
-
AI content may include mistakes. Learn more
Google apps